Background: The use of poor quality antimalarial medicines, including the use of nonrecommended medicines for treatment such as sulfadoxine-pyrimethamine (SP) monotherapy, undermines malaria control and elimination efforts. Furthermore, the use of subtherapeutic doses of the active ingredient(s) can theoretically promote the emergence and transmission of drug resistant parasites.
Introduction
The spread of antimalarial resistance is hampering malaria control and elimination efforts globally (Ambroise- Thomas, 2012; World Health Organization, 2010a) . Poor quality antimalarials can be categorised into three main groups: falsified; substandard; and degraded (WorldWide Antimalarial Resistance Network, 2010) . Each of these can be a source of subtherapeutic doses of the active ingredient(s), which promote the emergence and transmission of drug resistant parasites through selection pressures (Barnes, Watkins, & White, 2008; Simpson et al., 2000; White et al., 2009) . Falsified antimalarials are those that are fraudulently made and typically contain an incorrect amount of active ingredient, incorrect active ingredient, toxic substances, or no active ingredient. Substandard antimalarials are those made by licenced companies but use poor manufacturing practices. Degraded antimalarials degrade from their initial quality due to inadequate storage conditions, such as excessive heat. In addition, within poor quality antimalarials, we include those that are not recommended in the World Health Organization (WHO) guidelines.
Approximately 30% of antimalarial medicines in Africa and Asia are considered to be falsified or substandard (AmbroiseThomas, 2012; Newton, Green, & Fernandez, 2009 ). The outcome for those receiving poor quality antimalarials ranges from prolonged malaria symptoms, unexpected side effects, financial strain due to loss of income or healthcare costs, or even death (Ambroise- Thomas, 2012; Newton, Green, Fern andez, Day, & White, 2006; Tabernero, Fern andez, Green, Guerin, & Newton, 2014) . In Kenya, prior to 2004, sulfadoxine-pyrimethamine (SP) had been recommended as first-line for treatment of malaria. Due to increasing resistance to SP, stemming from mutations in the P. falciparum dihydrofolate reductase (DHFR) gene, which affects pyrimethamine, and the dihydropteroate synthase (DHPS) gene, which affects sulfadoxine, Kenya adopted artemetherlumefantrine (AL) as its first-line treatment in 2004. In 2001, WHO recommended the use of artemisinin-based combination therapies (ACTs) as first-line policy (World Health Organization, 2010b) . In December 2007, a report was produced surveying the antimalarial medicines available in Kenya and their quality. The researchers identified a wide range of products on the market, the majority of which were not in-line with the new national guidelines, and a high proportion were either unregistered or of low quality (Ministry of Health Republic of Kenya, 2007) .
The effect of antimalarial use on the transmission of resistance has been modelled previously (Hastings, 2006; Klein, 2014; Koella & Antia, 2003; Mackinnon & Hastings, 1998; Tchuenche, Chiyaka, Chan, Matthews, & Mayer, 2011) . Notably, the models currently available do not take into account the quality or percentage of antimalarial active ingredient and its effect on transmission. As summarised by Koella and Antia (2003) , part of the issue preventing these resistance transmission models from being developed and used is a lack of complete, comprehensive datasets for key parameters. Since their model was published, work has been carried out to look at the effect of drug quality on resistance within mice (Huijben et al., 2010a (Huijben et al., , 2013 and the effect of treatment in humans with SP-resistant infections (Barnes, Little, et al., 2008; M endez et al., 2007) .
Here we develop a new model to explore the impact of antimalarial quality, defined as poor quality SP, as defined above, and good quality AL, on the transmission of SP antimalarial resistance in Plasmodium falciparum. To assist in more realistic parameterisation of the model, we applied the model to Kenya in 2006, rather than Kenya being a focus for actual predictions. The model assumes that low to moderate SP-resistance conferred by mutations in the DHFR gene, the target of pyrimethamine, has already been established within both human and mosquito populations.
Materials and methods

Model structure
We developed a deterministic compartmental model to explore the impact of antimalarial quality on the transmission of P. falciparum SP resistance (Fig. 1) . The model quantifies the transmission dynamics of SP-sensitive (denoted w) and SP-resistant (denoted r) P. falciparum between female Anopheles mosquitoes and humans. The human-mosquito system is modelled using ordinary differential equations (ODEs) (Eq. (A1), Appendix A1). Humans may be infected by SP-sensitive strains ðwÞ, SPresistant strains ðrÞ, or both ðwrÞ. Resistance to SP was defined as the presence of DHFR-51 and DHFR-108 pyrimethamine resistance-conferring mutations (M endez et al., 2007) , used as proxy for all low to moderate SP-resistant conferring mutations in P. falciparum (Sridaran et al., 2010) . At baseline, the percentage of humans and mosquitoes with SP-resistant infections was set to 42% (Kum, Thorburn, Ghilagaber, Gil, & Bj€ orkman, 2013; Spalding et al., 2010) and mixed infections was set to 8% (Kum et al., 2013) .
Humans free of P. falciparum were classified as susceptible and denoted by SðHÞ. When transmission of sporozoites occurs from female An. mosquitoes to humans during a blood meal, the human moves into the exposed class (EðHÞ i Þ at the rate b H;i .
The script i indicates a SP-sensitive (i is w) or SP-resistant (i is r) P. falciparum infection. Due to the difference in the latent periods for asexual P. falciparum and gametocytes, it is assumed that antimalarial treatment is sought while in the exposed class to treat malaria symptoms as part of the asexual lifecycle (Poser & Bruyn, 1999) . There are four types of treatment available, each used as a proxy for 'good quality' or 'poor quality' treatments. Infected humans receive each treatment type with probability q d , where the subscript d is q for a full dose of AL (good quality); m for a full-dose of SP monotherapy (poor quality); p for a half-dose SP monotherapy (poor quality); and n for no treatment, either through no antimalarial compound within the medicine sought or choosing not to seek treatment (poor quality). Following the gametocyte latency period, those in the exposed class move into the infectious class at rate s H , which is assumed to be equal for both SP-sensitive and SP-resistant infections. The length of infectiousness and probability of transmission of gametocytes from infected humans to mosquitoes are specified for each strain ði ¼ w; r or wrÞ and treatment ðd ¼ q; m; p or nÞ combination. The recovery rate is defined by g i;d . Natural immunity is gained at rate g R , among those who do not receive treatment (Bousema & Drakeley, 2011) , and lost at rate r. The protective nature and rates for gaining and losing natural immunity are also assumed to be independent of P. falciparum infection type. Female Anopheles mosquitoes may be susceptible ðS M ð ÞÞ, exposed ðEðMÞ i Þ, or infected ðIðMÞ i Þ. Movement from susceptible to an exposed class, after the transmission of P. falciparum during a blood meal, occurs at rate b M;i ; where i is w for SP-sensitive parasites or r for SP-resistant P. falciparum. The rate of transmission is defined as the product of the daily mosquito biting rate ðcÞ and the probability of transmission given parasite strain and drug treatment received by the human (Z w orZ r ). We assume that An. mosquitoes can only be infected by one strain of P. falciparum gametocytes (i.e., no mixed infections), and in the occurrence that a susceptible mosquito feeds on a human host with a mixed infection, the probability of the SP-sensitive strain being selected over the SP-resistant strain ðP w Þ and proceeding through the mosquito's midgut and onto the salivary gland, is set at 0.6, assigning a relatively small fitness cost to resistance (Appendix D1). Following the latent period, the mosquito enters the infectious class ðIðMÞ i Þ at rate s M , and it is assumed that they do not recover from their infection due to their short lifespans (Mandal, Sarkar, & Sinha, 2011) . The parameters used in the model are defined in Tables 1 and 2 . Additional parameters, including details on the calculations of mosquito and human demographic turnover rates can be found in Appendices BeE. The impact of SP on the level of gametocytes in humans has been extensively researched (Barnes, Little, et al., 2008; Bousema & Drakeley, 2011; M endez et al., 2007) . We calculated an estimate for the length of gametocyte carriage and the probability of transmission when treated with a full dose pyrimethamine, half dose (using 50% or 37.5% of a full dose) of pyrimethamine, or no treatment (Huijben et al., 2010b (Huijben et al., , 2013 (Huijben et al., , 2010a , and then calibrated these scenarios against human SP monotherapy studies (Barnes, Little, et al., 2008; M endez et al., 2007) (Appendix C2eC3). The model simulations were run at the 2006 baseline level for all parameters, with the initial conditions (Appendix A2) chosen to match surveillance data observed in Kenya in 2006. The system was solved for 1 year (2006) , and the results analysed. All analysis were carried out in Mathworks Matlab 2012a, using the ODE15s solver. Fig. 1 . A summary of the structure of the mathematical model showing the movement between compartments of SP-sensitive and SP-resistant Plasmodium falciparum in humans and female Anopheles mosquitoes (blue solid line). The transmission of gametocytes (infected human to susceptible mosquito) and sporozoites (infected mosquito to susceptible human) during a blood meal, is depicted by the red dotted line for SP-sensitive, and a dark green dotted line for SPresistant.
Gametocyte carriage and infectiousness
The parameter values for the duration of gametocyte carriage and the probability a mosquito takes up a mature (infectious) gametocyte during a blood meal, given the infection-type and treatment received by the patient, utilised a combination of data from mice malaria studies for pyrimethamine (Huijben et al., 2010b (Huijben et al., , 2013 (Huijben et al., , 2010a and human SP studies (Barnes, Little, et al., 2008; M endez et al., 2007) . Pyrimethamine (not in combination with sulfadoxine) mice studies were used to inform parameterisation due to the availability of data on pyrimethamine, with no such data was available on SP. This method is described in Appendices C2eC3.
The expected duration of gametocyte carriage, given treatment scenarios, were calculated and compared to the 2006 baseline treatment level (70% AL use (assumed, Appendix C1), 7% full-dose SP monotherapy (Demographic and Health Surveys (various), 2003e2012), 3% half-dose SP monotherapy (Minzi et al., 2003; Newton et al., 2006; Tabernero et al., 2014) , and 20% no treatment (Chuma, Gilson, & Molyneux, 2007) ), in Fig. 2A and Table 3 . An increase in the use of fulldose or half-dose SP monotherapy use, or no treatment by 1% (with a corresponding 1% decrease in AL use), resulted in an increase in the duration of gametocyte carriage from baseline (16.1 days) of 2½ hour, 3 h and 16 h, respectively. However, exclusive use of either full-dose or half-dose SP (all other treatments set to 0%), results in the duration decreasing from baseline (3.3 days and 1.6 days, respectively); whereas increasing when no treatment is exclusively used by 50.9 days; indicating no treatment has a large impact on carriage. In contrast, as the percentage of AL treatment increases, a decrease in the average duration of gametocyte carriage is observed (2 h per 1% increase), down to an eventual duration of 2 days when used exclusively. The calculated probability of mosquitoes taking up infectious gametocytes during a blood meal also increased in response to greater use of full-and half-dose SP monotherapy, and no treatment (Fig. 2BeC, Table 3 ). In settings where SP resistance is already firmly established, a 1% increase in full-dose SP monotherapy resulted in a larger percentage increase in SP-resistant infectiousness, than sensitive infectiousness (2.5% v 1.1%). This is further highlighted under the scenario of exclusive use of full-dose SP, where results indicate a 200.7% increase in the probability of mosquitoes taking up SP-resistant P. falciparum, compared to a 65.2% increase in SP-sensitive P. falciparum. In contrast, 1% increases in half-dose SP or no treatment use had a greater percentage increase in the probability of mosquitoes taking up SP-sensitive P. falciparum (0.5% and 1.6%, respectively) compared to SP-resistant P. falciparum (0.1% and 1.5%, respectively). However, when used exclusively, half-dose SP had the greatest percentage increase in SP-resistant P. falciparum compared to SP-sensitive (35.3% v 12.2%); with exclusive use of no treatment resulting in a similarly large percentage increase for both (98.6% and 119.3%, respectively). Changes in the use of AL resulted in a greater decrease in the probability of SP-resistant P. falciparum being taken up by mosquitoes, compared to SPsensitive P. falciparum (2.4% v 1.0%, for 1% increase; and 46.7% v 41.1%, when exclusively used).
Measuring the effect on transmission
The main outcome of interest is the impact of antimalarial quality on the total proportion of SP-resistant infections (resistant and mixed infections) in the human population (∅, Eq. (1) 
Here XðHÞ denotes the human classes (excluding acquired immunity), where the subscript w and r once again denote SPsensitive and SP-resistant P. falciparum, respectively.
In addition to the proportion of SP-resistant infections, we also measured the expected number of malaria cases in humans.
Model accuracy
To validate our results, we performed a sensitivity analysis, and compared baseline model predictions against estimates found in the literature. A one-way sensitivity analysis was carried out, where each parameter was individually changed to the minimum and maximum value in its defined parameter range, and the change in the total proportion of SP-resistant infections in the human population was calculated. Parameters that inferred a change of greater than ±10% were considered to be significant during the sensitivity analysis.
Results
To quantify the impact of antimalarial quality on the transmission of SP resistance in P. falciparum, we varied the amount of good and poor quality antimalarial use in the population. Any change in antimalarial use that assists the survival and propagation of antimalarial resistance within human and mosquito populations highlights the need for better control and regulations of the use and availability of these medicines in order to offer safe and effective treatment.
Malaria cases (human)
At baseline, our model predicts 10,807,000 malaria cases in Kenya during 2006 (Fig. 3A, Table 4 ). An increase in the use of poor quality antimalarial use predicts a greater number of malaria cases, with the greatest increase observed under the scenario of full-dose SP being exclusively used (776.9%), followed by no treatment (773.6%) and the exclusive use of half-dose SP use (558.6%). This suggests that people may experience multiple malaria infections within one calendar year (population size 36,757,498 (The World Bank., 2006e2013g) ). Under the exclusive use of AL, the model predicts that the number of malaria cases in Kenya for 2006 could have been 2,978,200 (a reduction of 72.5% from baseline). The proportion of malaria cases that contained SP-resistant P. falciparum reflects these increases under each scenario of SP use, where exclusive use of full-dose SP increases by 18.4% from baseline, and half-dose increases by 13.8% (Fig. 3B, Table 4 ). Decreases in the proportion of SP-resistant infections were observed when no treatment was used (À5.8%) and the exclusive use of AL (À1.8%).
Results validation
Key 2006 baseline model output was compared to empirical estimates for the Kenyan population (Table 5 ), indicating our model predicted these outputs within an acceptable range. For the sensitivity analysis, parameters that inferred a change in the total proportion of SP-resistant infections in the human population of greater than ±10% were considered to be significant (Table 6 ). As seen with other malaria models (Mandal et al., 2011) , our model was sensitive to mosquito parameters, such as the proportion of mosquitoes to humans, the daily rate female An. mosquitoes reach adulthood, and the probability of transmission of SP-sensitive and SP-resistant sporozoites during a blood meal. Additionally, the expected gametocyte clearances of SP-sensitive and SP-resistant gametocytes when treated with AL were found to significantly influence model outputs. The full sensitivity analysis is available in Appendix F. 
Table 4
The impact of changes in the percentage use of treatments (after 365 days) on the expected number of malaria cases in Kenya for 2006 and the proportion of resistant infections (percentage change), when compared to the 2006 model baseline. The 2006 model baseline treatment use was set to 70% AL treatment ðqqÞ, 7% full-dose SP monotherapy ðqmÞ, 3% half-dose SP monotherapy ðqpÞ, and 20% no treatment ðqnÞ; and for the exclusive use of a treatment (100% use), all other treatments were set to 0%.
Drug Use Scenarios
Expected malaria cases (2006 
Discussion
Our model suggests that once SP resistance is widespread, as was the case in Kenya in 2006, an increase in poor quality antimalarial use (focusing on SP) results in an increase in: (i) the number of human malaria cases (Fig. 3A) , and (ii) of these cases, an increase in the proportion of SP-resistant infections in humans (full-or half-dose SP used, Fig. 3B ), when compared to good quality antimalarial use (AL). The predicted increase in malaria cases is of concern, where the scenario of full-dose SP being exclusively used (þ776.9%), followed by no treatment (þ773.6%) and the exclusive use of half-dose SP use (þ558.6%), yield large increases; whereas the exclusive use of AL results in a marked decrease in the number of expected cases (À72.5%). The predicted increase in resistant-containing infections under SP drug pressure is supported by findings from Hastings (Hastings, 2006) . Our findings suggest that a delay in P. falciparum clearance in humans, due to SP-resistance and/or inadequate antimalarial active ingredient, allows for prolonged transmission of SP-resistant gametocytes, hence ensuring their propagation throughout human and mosquito populations.
There are clear examples of substandard SP circulating in east Africa and elsewhere (see http://www.wwarn.org/ aqsurveyor/#0). A common problem has been impaired drug dissolution due to poor manufacturing, despite having the correct amounts of SP in the tablet, which result in low blood SP drug levels (Leslie et al., 2009; White et al., 2009 ). The impacts described here for reduced dosage of SP will also apply to this situation of reduced bioavailability. In addition, systematic under-dosing of antimalarials, common in pregnancy and young children, has been shown to impact efficacy, with theoretical impacts of the selection of drug resistance (Barnes, Watkins, & White, 2008; Sambol et al., 2015) . In all these cases, the key variable will be the antimalarial levels parasites are exposed to, reflecting both antimalarial content and bioavailability.
The impact of antimalarial quality on mortality could not be explicitly explored as the model assumes that the proportion of malaria-specific mortality ðm I Þ is proportional to the prevalence of malaria and hence driven by this relationship. This additionally acts to drive the overall mortality.
The accuracy of the model indicated larger percentage errors in the predicted malaria cases and malaria deaths for 2006 (Table 5) . However, this simulated number of malaria cases is below the 15 million cases estimated to have occurred in Kenya in 2006 (World Health Organization, 2010b , where under-reporting is considered a factor. This under-reporting is also assumed for malarial deaths, where there are discrepancies between the estimated (overall) deaths in Kenya in 2006 (The World Bank, 2006 -2013c World Health Organization, 2010b ) (Appendix B6). The parameterisation of the transmissibility and infectiousness of gametocytes under each treatment type utilised a combination of data from mice malaria studies for pyrimethamine (Huijben et al., 2010b (Huijben et al., , 2013 (Huijben et al., , 2010a and human SP studies (Barnes, Little, et al., 2008; M endez et al., 2007) . The use of these calculated estimates introduces a margin of error; as well as the possible under-estimation of the transmissibility and infectiousness of those receiving a half-dose of SP (Appendix C3.2). The impact of antimalarial quality on the duration of gametocyte carriage seems plausible, with the largest increase predicted from increases in those who receive no treatment. Increases in carriage duration were observed with increases in the percentage SP use, with half-dose SP monotherapy showing more marked increases in carriage duration than full-dose SP monotherapy. This may be explained by SP-sensitive infections being cleared more slowly following sub-therapeutic concentrations of antimalarial medicine, then when using full-dose SP, thereby providing a longer period for gametocytes to remain in circulation. Interestingly, this relationship was not observed when considering pyrimethamine-resistant gametocyte density in mice, despite peak density and carriage often being correlated (Huijben et al., 2013) . The limitations in approximating these parameters further highlight the need for more data in this area, as well as other more currently utilised antimalarial drugs.
The model assumed that SP-resistance is conferred by mutations in the DHFR gene, omitting other possible mutations conferring sulfadoxine-resistance, or other mutations in the DHFR gene such as C59R or the high level resistance-conferring I15L mutation (Rosenthal, 2013) . The selection of low to moderate SP resistance was due to the availability of data (or lack thereof), highlighting the need for further research in this area.
It must be noted that both symptomatic and asymptomatic infections (Bousema, Okell, Felger, & Drakeley, 2014) , as well as those with acquired immunity (Klein, Smith, Boni, & Laxminarayan, 2008) , harbour gametocytes. The transmission potential of asymptomatic or acquired immune individuals were not included as a source of transmission, as they are outside of the scope of this study. Additionally, the model parameterised the mortality of mosquitoes irrespective of infection-status; did not allow mixed infections within the mosquito population; and a fitness-cost was assigned to SP-resistant gametocytes when mixed infections were taken up during a blood meal. A more detailed discussion of these assumptions and limitations is provided in Appendix G.
The effect of antimalarial treatment on gametogenesis and infectiousness differs depending on the antimalarial class. A key assumption in using poor quality SP as a proxy for the use of all poor quality antimalarial use is that we assume that all antimalarials have the same propensity to generate gametocytes and effect on gametocyte infectiousness, which is not the case. For example, ACT use is associated with a lower rate of gametocyte carriage (Bousema & Drakeley, 2011) , highlighting the need for further studies.
Conclusions
The model predicts that an increase in the use of poor quality antimalarials, for which SP is an appropriate proxy, results in an increase in the transmission of antimalarial resistant malaria, providing insight into the link between poor quality antimalarial medicine use and resistance. The loss of antimalarial effectiveness is hampering malaria eradication efforts worldwide, and the continued availability and use of falsified, substandard, degraded and non-WHO recommended antimalarials are highly likely to facilitate the spread of resistance. In order to continue to effectively eradicate malaria, the availability and use of these antimalarials must be addressed by drug regulatory authorities and international organisations.
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A2. Initial conditions
The set of initial conditions for each class of the model are defined in Table A2 .1.
B. Human parameters
The model parameters for the human population are defined in Table B .1, along with the parameter values used, the parameter range, and the published reference or the section of the Appendices where this parameter is defined. 
where c denotes the number of births in Kenya, in 2006; z denotes the average number of births per female; U Н denotes the daily birth rate of humans; j denotes the proportion of Kenyan population that are female;
denotes the probability of being of childbearing age; and x H denotes the expected human lifespan (days).
B2. Movement from susceptible to exposed classes ðb H;i Þ
The expected rate of movement of humans from being susceptible to exposed to P. falciparum, during a blood meal when sporozoites are introduced through the salivary gland of the female An. mosquito, is defined by
where i denotes the P. falciparum strain (i ¼ w for SP-sensitive or i ¼ r for SP-resistant); c denotes the female An. mosquito daily biting rate; and T i denotes the transmission probability of strain i from mosquito to human.
B3. Movement from exposed to infected ðs H Þ
The expected time to infectious gametocytes, y, in days is defined by
where P Н denotes the latency period of asexual parasites in humans (days); G I denotes the time until the initial wave of asexual P. falciparum (days); and G M denotes the time for gametocytes to mature in order to be infectious to female An. mosquitoes (days).
Therefore, the rate of human movement from being exposed to P. falciparum (during a blood meal), to being infectious (mature gametocytes), is given by 
where i ¼ w for SP-sensitive P. falciparum, i ¼ r for SP-resistant P. falciparum, i ¼ wr for mixed P. falciparum infection; d ¼ q for good quality AL treatment, d ¼ m for full-dose SP treatment, d ¼ p for half-dose SP treatment and d ¼ n for no antimalarial treatment; P Н denotes the latency period of asexual P. falciparum in humans (days); h denotes the delay in seeking treatment (days); ε i;d denotes the estimated time to recovery in days (see Appendix C2); and y denotes the expected time to infectious gametocytes (days) (Eq. (B3.1) ).
B5. Movement from infected to acquired immunity ðg R Þ
Immunity to malaria is defined by Bruce-Chwatt (1980) as "the state of resistance to infection brought about by all those processes which are involved in destroying the plasmodia or by limiting their multiplication", and can be passive or active. Passive immunity is conferred from mother to child or through vaccinations (Doolan, Dobano, & Baird, 2009 ). For the purposes of this model, we assume passive immunity cannot be gained. Actively acquired immunity is assumed to be temporarily gained after continuous exposure, as used in the model by Labadin et al. (2009) . Acquired immunity has been found to be delayed in the presence of intermittent or prophylaxis treatment (Doolan et al., 2009) , and additionally in full dose treatment, as parasites are eradicated (Long, Nakazawa, Huaman, & Kanbara, 2002) . In research carried out by Long et al. (2002) on mice, lower doses of antimalarial treatment better enabled the mice to acquire protective immunity than the higher doses. We assume that once acquired immunity is gained, protection is afforded against both SP-sensitive and SP-resistant infections.
The maximum expected rate of acquired immunity gained is defined by Eq. (B5.1) (Labadin et al., 2009) , resulting in the parameter range for g R of [0, 0.0018].
where g R denotes the rate acquired immunity is gained; q denotes the daily rate of building effective immunity; and s denotes the daily rate of recovery. The difference in estimates of mortality provided by the World Bank and the WHO World Malaria Report indicates the possibility of under-reporting in the estimates obtained by the WHO, for both overall and malaria-specific mortality. The number of malaria deaths reported by the WHO was adjusted by an "under-reporting" factor calculated in Eq. (B6.1).
Estimated Malaria DeathsðcountÞ
The daily rate of mortality is defined into two groups: (i) malaria-specific mortality ðm I Þ and (ii) other mortality ðm O Þ. Malaria-specific mortality occurs once humans are within the infected class; and other deaths occur in all other classes of the model, where these non-malarial associated deaths may be due to other illnesses, old age, accidents, among other causes.
The calculation for the daily rate of malaria-specific mortality ðm I Þ is defined below. The proportion of those infected with P. falciparum who die, x, in 2006 is
An estimate of the overall rate of recovery from infected to susceptible classes, g, at baseline is:
Therefore, the daily rate of malaria-specific mortality ðm I Þ while the human is infected (i.e. has infectious gametocytes) is approximately:
It must be noted that the estimate of malaria-specific mortality does not include the time period the patient is in the exposed class and symptomatic (asexual P. falciparum) but not infectious (mature gametocytes). In addition to this, the calculation for mortality is affected by the percentage use of antimalarial medicines. For this reason, it was defined at the 2006 baseline and cannot be explored under different drug use scenarios (results section). Finally, this calculation assumes that the "total population minus malaria cases" is an accurate estimate of the number of people who do not get malaria. It must be noted that people can get more than one malaria infection within the calendar year.
The other mortality ðm O Þ is assumed to be approximately equal to the overall mortality rate in humans ðm H Þ, defined as 1/ (life expectancy), because the proportion of those with malaria who die is so small (see Eq. (B6.4)).
C. Treatment parameters
The treatment-based model parameters are defined in Table C .1, along with the parameter values used, the parameter range, and the published reference or the section of the Appendices where this parameter is defined. Insight into the quality of antimalarial medicines, especially the percentage of falsified medicines, has been informed by numerous studies; however, accurate estimates are hard to come by. In 2006, Newton et al. (2006) estimated the percentage of falsified medicines ranges from 1% to 50% worldwide. An analysis of the WorldWide Antimalarial Resistance Network database found that out of 9348 antimalarial medicines sampled, 30.1% failed chemical or packaging quality tests, of which: 39.3% were classified as falsified; 2.3% as substandard medicines; and 58.3% poor quality without evidence available to classify them as substandard or falsified . A study released in 2003, analysing the quality of SP tablets sold by private wholesale pharmacies in Dar Es Salaam, Tanzania, found that 8/18 (44%) of SP samples failed assay tests for content and dissolution tests (Minzi et al., 2003) .
Following this evidence, the probability of receiving full-dose SP ðq m Þ was set to 0.07; the probability of receiving half-dose SP ðq p Þ was set to 0.03; the probability of not receiving any antimalarial treatment ðq n Þ was set to 0.20; and the probability of receiving AL treatment ðÞ was assumed to be the remainder (Eq. (C1.1)), at baseline.
C2. Gametocyte clearance (days) post-treatment ðε i;d Þ
C2.1. Artemether-Lumefantrine treatment sought
In the literature, Bousema et al. (2006) found 16.0% (12 out of 75) of children treated with AL had gametocytemia on day; and Sutherland et al. (2005) found 7.94% (30 out of 378) treated children were carriers of gametocytes on day 28 posttreatment. However, Sawa et al. (2013) found an average of 5:5 days of gametocyte carriage post-treatment (95% CI: 3.6e8.5 days) of children treated with AL who remained asexual parasite free during follow-up. For this reason, we feel it is a reasonable assumption that the patient has gametocytemia until day 14 and then moves back to the susceptible class, given that the number of humans carrying gametocytes past day 28 is small. ε w;q ¼ ε r;q ¼ ε wr;q ¼ 14 days½7; 28 (C2.1.1)
where ε i;d denotes the estimated days for gametocyte clearance post-treatment, for P. falciparum strain i and drug treatment d; and the parameter range is denoted [minimum, maximum].
C2.2. Sulfadoxine-Pyrimethamine treatment sought
The data used to inform the asexual and gametocyte clearance rates when treated with SP were calculated using the combination of mice data (pyrimethamine treatment) (Huijben et al., 2010b (Huijben et al., , 2013 (Huijben et al., , 2010a and human SP studies carried out in South Africa (Barnes, Little, et al., 2008) and Columbia (M endez et al., 2007) . The mice studies researched the effect of pyrimethamine (not in combination with sulfadoxine) on gametocyte densities and the length of infectivity over a maximum of 28 days (Huijben et al., 2010a (Huijben et al., , 2013 . The experimental design was developed to simulate the emergence of resistance, using two genetically distinct P. chabaudi clonal lineages in each study: drug-resistant AS12265 (pyr-1A) and drug-sensitive AJ5154 (Huijben et al., 2010a) ; and drug-susceptible clone AJ5p and pyrimethamine-resistant clone AS6p(pyr1A) (Huijben et al., 2013) . The experiment was carried out in six to eight week-old female C57Bl/6J laboratory mice, with treatment taking place six days post-inoculation. In mixed infections, 10 6 pyrimethamine-sensitive parasites were inoculated, followed by~25
pyrimethamine-resistant parasites five days after the experiment began, to simulate the emergence of resistance. The estimates for half-dose SP treatments were calculated from experimental data using on 50% of a full dose of pyrimethamine (Huijben et al., 2013) and 37.5% of a full dose of pyrimethamine (Huijben et al., 2010a) . Figure C2 .2.1 shows a summary of data obtained.
Estimates for the expected gametocyte clearance time for humans in days, corresponding to each P. falciparum infection type i when using half-dose SP monotherapy did not exist at the time of developing this model, so multiple studies and assumptions were used to calculate these values. Estimates of the time to recover were calculated using Eq. (C2.2.1), where the ratio of expected recovery time of mice treated with half-dose pyrimethamine to full-dose pyrimethamine treatment is multiplied by the expected time to recovery in humans treated with full-dose SP. A summary of the parameter values obtained from the human and mice studies are provided in Table C2 where EðHÞ i;m denotes the gametocyte clearance time in humans for each P. falciparum strain i when treated with full-dose SP, as found by Barnes, Little, et al., 2008 ; EðMÞ i;p or n denotes the gametocyte clearance time in mice for each P. chabaudi strain i when treated with half-dose SP ðpÞ or no treatment ðnÞ, as found by Huijben et al. (2010a) (for i ¼ w) or Huijben et al. (2013) (for i ¼ r or wr); and EðMÞ i;m denotes the gametocyte clearance time in mice for each P. chabaudi strain i when treated with full-dose pyrimethmaine, as found by Huijben et al. (2010a) (for i ¼ w) or Huijben et al. (2013) (for i ¼ r or wr). Fig. C2 .2.1. The daily P. chabaudi gametocyte density in mice post-pyrimethamine treatment for (A) pyrimethamine-sensitive gametocytes, (B) pyrimethamineresistant gametocytes, and (C) mixed infection gametocytes. The purple line denotes the gametocyte density for a 100% pyrimethamine treatment. The green line denotes the gametocyte density of 37.5% of a full dose of pyrimethamine treatment for (A) and 50% of a full dose of pyrimethamine treatment for (B) and (C). Data provided by Huijben et al. (2013 Huijben et al. ( , 2010a Huijben et al. ( , 2010b .
The expected gametocyte recovery time in days ðε i;d Þ used to parameterise the model, along with the parameter range ([minimum, maximum]), is provided in Table C2 .2.2.
C3. Infectiousness of humans to mosquitoes ðZ i;d Þ
Barnes, Watkins, et al., 2008 identified a log-sigmoidal relationship between gametocyte density and infectivity to mosquitoes, with the probability of mosquito infection dependent on the prevalence, duration and density of gametocyte carriage in the human host. They further discussed that the infectivity given a "particular antimalarial treatment can be characterised as a function of blood gametocyte density and time, summing these over the acute and all subsequent recrudescence of that infection". Bousema et al. (2006) comment that the infectious mosquito reservoir determines the force of infection.
C3.1. No treatment sought
When no treatment is sought the expected probability of transmission ðZ n Þ is assumed equal for each infection type, Z n ¼ Z w;n ¼ Z r;n ¼ Z wr;n ¼ 0:2; range : 0:2 À 0:5 ðMandal et al:; 2011Þ (C3.1.1)
C3.2. Sulfadoxine-Pyrimethamine treatment
No specific dataset exists to inform the effect of SP treatment on infectiousness, so multiple studies were used to calculate estimates. A study carried out by M endez et al. (2007) was used to calculate the probability of gametocyte transmission when treated with full-dose SP monotherapy. The study recorded the proportion of infected mosquitoes with oocysts after treatment with SP, and the infectivity of those with and without SP-conferring mutations were calculated using membrane feeding assays. Resistance was defined as the presence of DHFR-51 and DHFR-108 SP resistance-conferring mutations. Figure C3 .2.1 shows the summary of the data produced in this study.
To calculate the expected probability of transmission from humans to mosquitoes, the area under the curve was calculated and then averaged over the number of days humans were found to be infectious (see Eq. (C3.2.1) and Fig. C3 .2.1, results in Table C3 .2.1). The calculation assumes a uniform average transmission probability, not taking into account days that humans are more "infectious" to mosquitoes than others; and that infectiousness to mosquitoes over the 28 day experimental period is indicative of the infectiousness of gametocytes in humans to mosquitoes over the timeframe of gametocytes being present (i.e. > 28 days). (Barnes, Little, et al., 2008 , M endez et al., 2007 ; and pyrimethaminesensitive ðwÞ, pyrimethamine-resistant ðrÞ and mixed infections ðwrÞ in mice Huijben et al. (2013 Huijben et al. ( , 2010a Huijben et al. ( , 2010b Reference(s) Barnes, Little, et al., 2008 M endez et al. Table C2 .2.2 Expected gametocyte clearance in humans (days). The expected clearance of P. falciparum gametocytes in humans, using a linear interpolation of SP treatment in humans (Barnes, Little, et al., 2008) and pyrimethamine treatment in mice studies (Huijben et al., 2010b (Huijben et al., , 2013 (Huijben et al., , 2010a , using Eq. (C2.2.1). A Estimated using mice data where the 37.5% of a full-dose of pyrimethamine treatment used (Huijben et al., 2010b (Huijben et al., , 2010a , whereas estimates from 50% of a full-dose of pyrimethamine treatment were used for the other parameter calculations (Huijben et al., 2013 where Z w or r;m denotes the average probability of transmission from humans to mosquitoes for SP-sensitive (w) or SPresistant (r) infections treated with SP monotherapy;
f ðtÞ w or r;m $dt denotes the area under the gametocyte densitytime curve, over 28 days; and 9 denotes the count of the number of days gametocytes are seen.
These estimates were then used to linearly interpolate the probability of transmission for mixed infections when full-dose SP monotherapy is used, and for all infections when half-dose SP monotherapy is used. As with the calculations for gametocyte clearance (Appendix C2), raw mice data provided by Huijben et al. (2013) was used (Fig. C3.2.2 and Fig. C3.2.3) . Figure C3 .2.2 shows that the mixed infection (dotted green line) appears to behave as the sum of the gametocyte densities of the SP drug-sensitive (w, purple line) and SP drug-resistant (r, blue line). As the mixed infection ðwrÞ predominates with the resistant ðrÞ peaks in the figure, it seems safe to assume that even with the data simulation where the mice is first infected with SP drug-sensitive ðwÞ P. falciparum first, then SP drugresistant ðrÞ P. falciparum are added after treatment has resumed at a vastly reduced number, the transmission probabilities, Z wr;m ¼ Z rw;m .
Assuming the probability of transmission is directly proportional to gametocyte density ( Fig. C3.2.3 and Table C3 .2.2), the infectivity to mosquitoes is calculated by multiplying the "known" infectivity for treatment with full-dose SP for strain i, by the ratio of gametocytes when treated with full-or half-dose pyrimethamine in the mice models (Huijben et al., 2010a (Huijben et al., , 2013 , see Eq. (C3.2.2). It must be noted, that initially 1 Â 10 6 pyrimethamine-sensitive parasites were inoculated followed five days later with~25 pyrimethamine-resistant parasites. We believe this experiment skews some of the results below, however a measure of the degree of skewing in uncertain. For this reason, we must clearly indicate that these values are our best estimate. f ðtÞ i;p $dt denotes the area under curve of the P. falciparum gametocytes density of strain i, treated with halfdose pyrimethamine ðaÞ from mice models (Huijben et al., 2013) ;
f ðtÞ i;m $dt denotes the area under curve of the P. falciparum gametocytes density of strain i, treated with full-dose pyrimethamine ðmÞ from mice models (Table C3 .2.2) (Huijben et al., 2010a (Huijben et al., , 2013 .
C3.3. Artemether-Lumefantrine treatment
In the literature, Bousema et al. (2006) found 3.6% (27 out of 750) of randomly selected children were infectious to mosquitoes on day seven (Table C3 .3.1), whereas the children tested over two years of age were found to be 18.7% infectious to mosquitoes. Sawa et al. (2013) found that 1.9% (42 out of 2292) of those treated with AL who had gametocytes were infectious to mosquitoes on day seven post treatment (Table C3. 3.2). In addition, Sutherland et al. (2005) found 0% (0 out of 195) children treated with AL were infectious to mosquitoes on day 28. This data has been amalgamated to produce Fig. C3.3 .1, which explores the infectivity of children treated with AL over time. The calculated total area of average gametocyte density in Fig. C3.2 .3, produced using data from Huijben et al. (2013 Bousema et al. (2006) ; Sawa et al. (2013); Sutherland et al. (2005) . where Z w; denotes the expected probability of transmission for SP-sensitive ðwÞ gametocytes from an infected human to mosquito; and q denotes the percentage use of AL treatment; m denotes the percentage use of full-dose SP; and n denotes the percentage who receive no treatment.
The line of best fit in Fig. C3 .3.1 indicates a poor fitting line (low R 2 ); however the calculated estimates of infectiousness are consistent with a study by M endez et al. (2007), where they found that SP-resistant parasites are 7e10 times more likely to infect mosquitoes after SP treatment, compared to no resistance. A summary of the expected probability of transmission of gametocytes of strain ðiÞ from human to mosquito during a blood meal, given the human drug treatment ðdÞ received by the human, is provided in Table C3 .3.3.
D. Transmission parameters
The transmission-based model parameters are defined in Table D .1, along with the parameter values used, the parameter range, and the published reference or the Appendix reference where this parameter is defined.
D1. Fitness cost in mosquito midgut ðP w Þ
The benefit that antimalarial resistance affords to a Plasmodium parasite may also cause a fitness cost (Fr€ oberg et al., 2013) . A study conducted by Mharakurwaa et al. (2011) identified a prevalence between 2% and 12% of antifolate resistant P. falciparum in the midguts of Anopheles arabiensis mosquitoes, which they discussed was very low, when in comparison, there was a high prevalence of resistance within the human population. In contrast, Costanzo and Hartl (2011) discusses that there is no discernible cost associated with maintaining resistance afforded by highly resistant triple or quadruple mutations in P. falciparum.
The model assumes that the female An. mosquito can only be infected with one strain of P. falciparum. In the occasion when the mosquito feeds on a human containing a mixed infection, the probability of P. falciparum SP-sensitive gametocytes being selected over SP-resistant gametocytes in the An. mosquitoes midgut is defined by P w , and set to 0.60 (where 0 P w 1). This value for P w assigns a small cost to resistance. This assumption was made in order to simplify the model. Table C3 .3.3 A summary of the expected probability of transmission of each P. falciparum strain ðiÞ from human to mosquito during a blood meal, given the antimalarial treatment.
A Low values believed to be a product of the experimental design to collect data. D2. . Transmission from humans to mosquitoes ðZ i Þ
The overall probability of gametocyte transmission from human to mosquito, for each P. falciparum infection ðiÞ, treatment ðdÞ combination, are as follows: 
E. Mosquito parameters
The model parameters for the female An. mosquito are defined in Table E .1, along with the parameter values used, the parameter range, and the published reference or the Appendix reference where this parameter is defined.
E1. Movement from susceptible to exposed ðb M;i Þ The P. falciparum transmission rate of female An. mosquitoes becoming exposed to P. falciparum gametocytes during a blood meal is defined by
where b M;w and b M;r denote the rate of female Anopheles mosquitoes becoming exposed to SP-sensitive ðwÞ and SP-resistant ðrÞ P. falciparum, respectively; c denotes the daily biting rate of female An. mosquitoes; andZ w andZ r denote the overall expected probability of transmission of SP-sensitive ðwÞ and SP-resistant ðrÞ gametocytes from human to mosquito, respectively (defined in Appendix D2).
E2. Movement from exposed to infected ðs M Þ
The daily rate of female An. mosquitoes movement from exposed to P. falciparum during a blood meal, to being infectious (sporozoites in salivary glands), is given by Eq. (E2.1). The model assumes that infected female An. mosquito do not recover from an infection due to their short lifespan, as assumed in many mathematical models (Mandal et al., 2011) . A To stabilise the model, we had to use a value less than the ranges identified in the literature.
E3. Mortality rates ðm M Þ
The mortality rate of female An. mosquitoes is assumed equal irrespective of P. falciparum infection status. In order to stabilise the model, we had to use a value ðm М ¼ 0:0280 Þ less than the ranges identified in the literature, a range of 0.05-0.5.
F. Sensitivity analysis
The sensitivity analysis results are found in Table F .1, where parameters that inferred a change in the total proportion of SPresistant infections in the human population of greater than ±10% were considered to be significant. 
G. Model Limitations
There are key assumptions and limitations in the model that have an impact on the findings; these are discussed in detail below.
G1. Estimating the transmissibility and infectiousness of gametocytes
The transmissibility of gametocytes is estimated from the duration and density of gametocyte carriage in humans over time. A well-known property of SP is its propensity to increase gametogenesis, which in turn increases the transmission of P. falciparum between humans and mosquitoes (Barnes, Little, et al., 2008 , Bousema & Drakeley, 2011 Hastings, 2006) . The data to inform the asexual and gametocyte clearance rates were calculated using a combination of mice malaria data for pyrimethamine (Huijben et al., 2010b (Huijben et al., , 2013 (Huijben et al., , 2010a , with human SP studies carried out in South Africa (Barnes, Little, et al., 2008) and Columbia (M endez et al., 2007) .
The mice studies looked at the effect of pyrimethamine (not in combination with sulfadoxine) on the gametocyte densities and length of infectivity over a maximum of 28 days (Huijben et al., 2010a (Huijben et al., , 2013 . In using these data, we had to assume that the estimates provided from pyrimethamine are a fair approximation of the estimates that would occur when used in combination with sulfadoxine.
We feel that the large differences in gametocyte densities and infectivity, as a result of half-and full-dose SP, are due to the experimental design of the mice studies. The pyrimethamine-sensitive infections were simulated by the injected the mice with sensitive parasites on Day One. Mixed infections had the same inoculation of pyrimethamine-sensitive parasites on Day One, followed by the introduction a small number of pyrimethamine-resistant parasites (approximately 25 parasites) on Day Five. In the pyrimethamine-resistant only studies, resistant parasites were inoculated on Day Five (25 parasites). Following this, we expect that this experimental design drives the lower SP-resistant estimates for the probability of gametocyte transmission from humans to mosquitoes ðZ r;d Þ for each treatment type ðdÞ, calculated in Appendix C3.2. This limitation highlights the need for more data in this field.
The infectiousness of SP-induced gametocytes may be less than gametocytes that differentiate without the stress of SP treatment, as found with the infectiousness of SP-induced gametocytes when compared to chloroquine-induced gametocytes. However, this decrease is thought to be offset by a higher prevalence and density of gametocytes following SP treatment (Barnes & White, 2005) .
For the above reasons, the accuracy of gametocyte-parameter estimates used in our model are unknown but are thought to underestimate the true value. An additional area of uncertainty in using these estimates was introduced by slight differences in experimental design between the two mice studies, when calculating estimates for a half-dose SP monotherapy treatment. These parameter estimates were calculated using data in which 50% of a full-dose of pyrimethamine (Huijben et al., 2013) and 37.5% of a full-dose of pyrimethamine (Huijben et al., 2010a) was used.
G2. Transmissibility in asymptomatic infections and acquired immunity
Both symptomatic and asymptomatic infections harbour gametocytes (Bousema et al., 2014) . The ability to transmit during asymptomatic infections are not included as they are outside of the scope of this study, as asymptomatic individuals have no reason to seek antimalarial treatment. In a similar manner, the model does not account for the possibility of gametocyte carriage, and hence transmission to mosquitoes, in those with acquired immunity, in contrast to work carried out by Klein et al. (2008) . We deemed this outside the scope of the study, as these individuals also would not need to seek treatment. A summary of the effect of acquired immunity on gametocyte density has been carried out by Carter and Graves (1988) and Bousema and Drakeley (2011) . Both papers surmise a conflict in findings by researchers; some conclude that patients with acquired immunity may be able to control asexual parasite densities better, and hence have lower gametocyte densities. However, others have shown that gametocyte densities may be at their highest in acquired immune populations. Bousema and Drakeley (2011) recommend longitudinal studies to further explore this relationship. Additionally, we do not account for any passive (maternal) immunity to malaria in infants.
G3. Patient adherence
Patient adherence is commonly identified as a confounding factor. In our case, SP is a single dose regimen, so we assumed perfect patient adherence. Artemether-lumefantrine in adults requires 24 tablets administered over 3 days. However, the model assumes that all AL treatment is of good quality, obtained from a reputable source and that all patients complete the treatment regime. However, there have recently been severe problems with the quality of AL in Africa World Health Organization, 2015) .
G4. Defining antimalarial resistance
The model assumes there is only one kind of resistance within the P. falciparum population, to SP. In reality, resistance has emerged to nearly all antimalarial compounds currently in use, and molecular markers associated with AL resistance have been described .
When defining SP resistance within our model, tolerance and low levels of resistance were excluded, but are expected to have an impact on the spread of resistance in P. falciparum (Tchuenche et al., 2011) .
G5. Mortality rates of mosquitoes
A constant mortality rate of mosquitoes was assumed, irrespective of P. falciparum-infection status, unlike the model produced by Tchuenche et al. (2011) . Our model also assumed that mosquitoes could not harbour a mixed infection ðwrÞ, and that the selection of SP-sensitive over resistant gametocytes during the bloodmeal, proceeding through to the mosquito's midgut and then salivary gland, occurs at P w ¼ 0:6. In their work, Huijben, Sim, Nelson, and Read (2011) found that resistant parasites are suppressed in the absence of treatment (irrespective of the number of competitors in multi-clonal environments), but have a marked advantage following drug treatment. They described a pattern of transient fitness advantage but it did not appear to have an effect on the overall transmission potential. Costanzo and Hartl (2011) found no discernible cost associated with maintaining resistance afforded by highly resistant triple or quadruple mutations in P. falciparum. However, in a study conducted by Mharakurwaa et al. (2011) a lower prevalence (2%e12%) of antifolate resistant parasites were found in the midgut's of Anopheles arabiensis mosquitoes, when compared to the high prevalence of resistance within the human population.
G6. Seasonality
Although the temporal resolution of the parameters were daily, the model outcomes were produced as yearly measures. For this reason, seasonality was not accounted for within the model structure.
